Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM116
- Development stage
- Preclinical
- Lead developer
- Programmable Medicine
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
PM116 (also referred to as H116) is a preclinical-stage hydroxyl dendrimer therapeutic (HDT), or 'dendranib,' consisting of a proprietary Janus kinase (JAK) inhibitor conjugated to a hydroxyl dendrimer (HD). Developed by Programmable Medicine and Ashvattha Therapeutics, PM116 is designed to selectively target activated myeloid cells (such as macrophages, dendritic cells, and neutrophils) in inflamed tissues, minimizing systemic exposure and off-target toxicities. In preclinical models of rheumatoid arthritis, PM116 demonstrated significant efficacy in reducing clinical arthritis scores, cartilage damage, pannus formation, inflammation, and bone resorption, comparable to the JAK inhibitor baricitinib.
02
Targets
Beyond the preview
Go deeper on PM116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM116.